Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-28T10:55:00.578Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of high-dose depot neuroleptics

Published online by Cambridge University Press:  02 January 2018

N. Purandare ,
L. Aitken ,
P. Joshi  and
C. S. Thomas
N. Purandare
Affiliation:
University Hospital of South Manchester
L. Aitken
Affiliation:
Stepping Hill Hospital Stockport
P. Joshi
Affiliation:
Stepping Hill Hospital
C. S. Thomas*
Affiliation:
Department of Psychiatry, University Hospital of South Manchester, Manchester M20 8LR
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims and methods

To identify and reduce the number of patients receiving depot neuroleptics above the British National Formulary maximum. The medical records were scrutinised and individual consultants were informed of the results.

Results

For the team involved in this audit there was a significant reduction in the prescription of high-dose depot medication, but this did not generalise to other teams.

Clinical implications

Different teams should repeat the audit and a new depot card has been developed.

Type
Original papers
Information
Psychiatric Bulletin , Volume 23 , Issue 6 , June 1999 , pp. 339 - 342
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 The Royal College of Psychiatrists

References

Cookson, I. B. (1987) The effect of a 50% reduction of Cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on high dose regime. International Clinical Psychopharmacology, 2, 141 149.CrossRefGoogle ScholarPubMed
Foster, P. (1989) Neuroleptic equivalence. Pharmaceutical Journal, 243, 431 432.Google Scholar
Hirsch, S. R. & Barnes, T. R. E. (1994) Clinical use of high-dose neuroleptics. British Journal of Psychiatry, 164, 94 96.CrossRefGoogle ScholarPubMed
Kane, J. M. (1994) The use of higher-dose antipsychotic medication. British Journal of Psychiatry, 164, 431 432.CrossRefGoogle ScholarPubMed
King, D. (1994) The use of high doses of neuroleptics: the current situation. International Clinical Psychopharmacology, 9, 75 78.Google ScholarPubMed
Mackay, A. V. P. (1994) High-dose antipsychotic medication. Advances in Psychiatric Treatment, 1, 16 22.CrossRefGoogle Scholar
Tarrier, N. (1992) Management and modification of residual positive psychotic symptoms. In Innovations in the Psychological Management of Schizophrenia (eds Birchwood, M. & Tarrier, N.). Chichester: John Wiley.Google Scholar
Taylor, J. R. & Cookson, I. B. (1997) Audit of out-patients on ‘higher dose’ antipsychotics. Psychiatric Bulletin, 21, 445 458.CrossRefGoogle Scholar
Thompson, C. (1994) The use of high-dose antipsychotic medication. British Journal of Psychiatry, 164, 448 458.CrossRefGoogle ScholarPubMed
Warner, J. P., Slade, R. & Barnes, T. R. E. (1995) Change in neuroleptic prescribing practice. Psychiatric Bulletin, 19, 237 239.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.